Clearside Biomedical Inc (NASDAQ:CLSD) shares were up 8.5% during mid-day trading on Friday . The stock traded as high as $1.20 and last traded at $1.15, approximately 766,100 shares traded hands during trading. A decline of 1% from the average daily volume of 771,629 shares. The stock had previously closed at $1.06.
Several equities analysts have recently issued reports on CLSD shares. ValuEngine raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Wedbush reissued a “buy” rating and set a $3.00 target price on shares of Clearside Biomedical in a research note on Monday, October 21st. Needham & Company LLC reissued a “hold” rating on shares of Clearside Biomedical in a research note on Thursday, October 31st. JMP Securities set a $3.00 target price on Clearside Biomedical and gave the company a “buy” rating in a research note on Thursday, August 22nd. Finally, Zacks Investment Research cut Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Monday, November 11th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $2.33.
The company has a market capitalization of $42.80 million, a PE ratio of -0.43 and a beta of -0.34. The company has a 50 day moving average of $0.97 and a two-hundred day moving average of $1.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.22 and a quick ratio of 2.22.
Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Wednesday, November 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Clearside Biomedical had a negative return on equity of 316.25% and a negative net margin of 18,893.49%. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.05 million. On average, equities analysts anticipate that Clearside Biomedical Inc will post -0.84 EPS for the current year.
Large investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in shares of Clearside Biomedical during the second quarter valued at $98,000. Vanguard Group Inc. lifted its holdings in shares of Clearside Biomedical by 66.9% during the second quarter. Vanguard Group Inc. now owns 924,485 shares of the company’s stock valued at $899,000 after purchasing an additional 370,690 shares in the last quarter. A.R.T. Advisors LLC bought a new position in shares of Clearside Biomedical during the second quarter valued at $95,000. Finally, Paloma Partners Management Co bought a new position in shares of Clearside Biomedical during the second quarter valued at $122,000. 10.18% of the stock is currently owned by hedge funds and other institutional investors.
Clearside Biomedical Company Profile (NASDAQ:CLSD)
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Recommended Story: Earnings Reports
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.